REG - AstraZeneca PLC - Total Voting Rights and Admission of Shares

AstraZenecaAnnouncement

Today 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260401:nRSA9426Ya&default-theme=true

RNS Number : 9426Y  AstraZeneca PLC  01 April 2026

1 April 2026

Total Voting Rights and Notification of Admission of Further Securities to
Trading (PRM 1.6.4R)

Total Voting Rights

The following notification is made in accordance with the UK Financial Conduct
Authority's Disclosure and Transparency Rule 5.6.1. As at 31 March 2026 the
issued share capital of AstraZeneca PLC with voting rights is 1,550,980,823
ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the
total number of voting rights in AstraZeneca PLC is 1,550,980,823.

The above figure for the total number of voting rights may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's
Disclosure and Transparency Rules.

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with The Public Offers and
Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

 1   Details of the issuer
 a)  Name                                                     AstraZeneca PLC
 b)  LEI                                                      PY6ZZQWO2IZFZC3IOL08
 2   Details of the transferable securities admitted to trading
 a)  Name, type and identification code                       Ordinary Shares of $0.25 each

                                                              ISIN: GB0009895292
 b)  Regulated market                                         London Stock Exchange - Main Market
 c)  Number of further securities issued and admitted         491
 d)  Total number of securities in issue following admission  1,550,980,823
 e)  Fungibility                                              Fully fungible with existing Ordinary Shares
 3   Admission details
 a)  Date of admission                                        Issued between 20 March 2026 to 31 March 2026 (admitted under a block
                                                              admission dated 29 January 2021)
 b)  Prospectus information                                   Prospectus: N/A

                                                              Supplementary: N/A

                                                              Company's webpage: https://www.astrazeneca.com (https://www.astrazeneca.com)

 c)  Coverage of notification                                 Admission of shares under the Company's employee share schemes from 20 March
                                                              2026 up to 31 March 2026, admitted to trading on the Main Market of the London
                                                              Stock Exchange under the Company's existing block admission of shares dated 29
                                                              January 2021.

 

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
 

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRWPUAGWUPQGBG



            Copyright 2019 Regulatory News Service, all rights reserved